These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 12188915)

  • 1. Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics.
    Zhu Z; Bohlen P; Witte L
    Curr Cancer Drug Targets; 2002 Jun; 2(2):135-56. PubMed ID: 12188915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor.
    Zhu Z; Witte L
    Invest New Drugs; 1999; 17(3):195-212. PubMed ID: 10665474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis-research frontiers. A basic science conference of the New York Academy of Medicine.
    Sepp-Lorenzino L; Pan BS
    Expert Opin Investig Drugs; 2000 Apr; 9(4):929-35. PubMed ID: 11185425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF receptor signaling in tumor angiogenesis.
    McMahon G
    Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
    Sledge GW
    Semin Oncol; 2002 Jun; 29(3 Suppl 11):104-10. PubMed ID: 12138404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.
    Schlaeppi JM; Wood JM
    Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications.
    Ellis LM; Takahashi Y; Liu W; Shaheen RM
    Oncologist; 2000; 5 Suppl 1():11-5. PubMed ID: 10804085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anti-angiogenic reagents].
    Shibuya M
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1182-7. PubMed ID: 10771693
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma.
    Arastéh K; Hannah A
    Oncologist; 2000; 5 Suppl 1():28-31. PubMed ID: 10804088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VEGF in brain tumors.
    Machein MR; Plate KH
    J Neurooncol; 2000; 50(1-2):109-20. PubMed ID: 11245271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
    Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
    J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignangies.
    Maio M; Altomonte M; Calabro L; Fonsatti E
    Front Biosci; 2001 Jun; 6():D776-84. PubMed ID: 11401781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities.
    Siemeister G; Martiny-Baron G; Marmé D
    Cancer Metastasis Rev; 1998 Jun; 17(2):241-8. PubMed ID: 9770121
    [No Abstract]   [Full Text] [Related]  

  • 18. Symposium on molecular pathogenesis of respiratory diseases and its clinical implication. 4. Molecular pathogenesis of lung cancer and its molecular targeted therapy.
    Sone S; Shinohara T; Nishioka Y; Yano S
    Intern Med; 2001 Feb; 40(2):167-70. PubMed ID: 11300157
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of vascular endothelial growth factor in the regulation of angiogenesis.
    Ferrara N
    Kidney Int; 1999 Sep; 56(3):794-814. PubMed ID: 10469350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [VEGF].
    Yoshiji H; Fukui H; Kuriyama S
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():189-94. PubMed ID: 11761939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.